Determination of power and sample size in the design of clinical trials with failure-time endpoints and interim analyses (Q33742213)

29 July 2017

1 reference

title

Determination of power and sample size in the design of clinical trials with failure-time endpoints and interim analyses (English)

1 reference

29 July 2017

Gu M

1

1 reference

29 July 2017

Lai TL

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

Contemporary Clinical Trials

29 July 2017

published in

1 reference

29 July 2017

volume

20

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

423-438

1 reference

Designing clinical trials with arbitrary specification of survival functions and for the log rank or generalized Wilcoxon test.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

A computer program for designing clinical trials with arbitrary survival curves and group sequential testing

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

Sample size determination in clinical trials with time-dependent rates of losses and noncompliance

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

Sample size calculation for complex clinical trials with survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

Group sequential procedures: calendar versus information time

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

Repeated assessment of results in clinical trials of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

A generalized Wilcoxon test for comparing arbitrarily singly-censored samples

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

Rank tests for survival analysis: a comparison by analogy with games.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

Asymptotically Efficient Rank Invariant Test Procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

An Adaptive Weighted Log-Rank Test with Application to Cancer Prevention and Screening Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

Changing frequency of interim analysis in sequential monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

Sample sizes for long-term medical trial with time-dependent dropout and event rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

Statistical aspects of early termination in the beta-blocker heart attack trial

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

Sample izes for medical trials with special reference to long-term therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

A user's review of commercial sample size software for design of biomedical studies using survival data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2899%2900021-5

7 January 2021

10.1016/S0197-2456(99)00021-5

Identifiers

DOI

1 reference

29 July 2017

1 reference